Voyager Therapeutics, Inc.
VYGR
$3.47
-$0.06-1.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.28M | 24.63M | 29.58M | 19.52M | 90.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.28M | 24.63M | 29.58M | 19.52M | 90.06M |
| Cost of Revenue | 35.58M | 30.24M | 34.45M | 27.09M | 25.76M |
| Gross Profit | -29.31M | -5.61M | -4.87M | -7.58M | 64.31M |
| SG&A Expenses | 8.99M | 8.17M | 10.15M | 8.61M | 10.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.58M | 38.41M | 44.60M | 35.70M | 36.00M |
| Operating Income | -38.30M | -13.78M | -15.03M | -16.18M | 54.06M |
| Income Before Tax | -33.90M | -9.00M | -10.12M | -11.32M | 57.22M |
| Income Tax Expenses | 584.00K | 43.00K | 24.00K | 14.00K | 822.00K |
| Earnings from Continuing Operations | -34.49M | -9.04M | -10.14M | -11.33M | 56.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.49M | -9.04M | -10.14M | -11.33M | 56.40M |
| EBIT | -38.30M | -13.78M | -15.03M | -16.18M | 54.06M |
| EBITDA | -37.29M | -12.65M | -13.63M | -14.99M | 55.40M |
| EPS Basic | -0.59 | -0.16 | -0.18 | -0.20 | 1.28 |
| Normalized Basic EPS | -0.37 | -0.10 | -0.11 | -0.12 | 0.81 |
| EPS Diluted | -0.60 | -0.16 | -0.18 | -0.20 | 1.25 |
| Normalized Diluted EPS | -0.37 | -0.10 | -0.11 | -0.12 | 0.79 |
| Average Basic Shares Outstanding | 57.97M | 57.85M | 57.72M | 57.12M | 43.98M |
| Average Diluted Shares Outstanding | 57.97M | 57.85M | 57.72M | 57.12M | 45.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |